Addex Therapeutics Funding Round

4/4/2023

Venture Equity

$5,000,000

Undisclosed

Addex intends to use the net proceeds from this offering to advance its portfolio of drug candidates and for general corporate purposes.

Private & Independent

Biopharmaceutical

Chemin des Mines, 9
Geneva, CH-1202
CH

Addex Therapeutics is a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of novel orally available, small molecule drugs known as allosteric modulators for neurological disorders. Allosteric modulators offer several potential advantages over conventional, non-allosteric molecules and may offer an improved therapeutic approach to conventional "orthosteric" small molecule or biological drugs. Addex's allosteric modulator drug discovery platform targets receptors and other proteins that are recognized as essential for therapeutic intervention. Addex's lead drug candidate, ADX71149 (mGlu2 positive allosteric modulator or PAM), developed in collaboration with Janssen Pharmaceuticals, Inc., is in a Phase 2a proof of concept clinical trial for the treatment of epilepsy.